Tradestie Institutional Equity Comparison Engine

AARD vs LMNX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AARD Overall Edge

AARD Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aardvark Therapeutics, Inc. Common Stock (AARD) driven by superior Growth & Margin, Options & Structure while LMNX counters with relative strength in Momentum & Technical. Fundamentally, AARD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus LMNX at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, AARD sits in UNCLASSIFIED (26th %ile IV; Dealer Gamma Walls on Pro) against LMNX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
AARD N/M vs LMNX N/M Fwd P/E
Growth & Margin Winner AARD
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner LMNX
1Y -88.4% vs -43.9% ยท 52W Pos 2% vs 5%
Options & Structure Winner AARD
UNCLASSIFIED (26th %ile IV) vs UNCLASSIFIED (N/A IV)
AARD NASDAQ
Aardvark Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.26
-5.26% 1D
Market Cap $29.1M
1M Return -66.67%
1Y Return -88.4%
Forward P/E N/M
Unified AI Score
57.5 / 100 HOLD
Tech 79.0 Fund 63.0 Flow 68.0 Mom 64.0
LMNX US Equity
LMNX
Institutional Equity
$9.16
+0.6% 1D
Market Cap N/A
1M Return +25.4%
1Y Return -43.87%
Forward P/E N/M
Unified AI Score
53.5 / 100 HOLD
Tech 63.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AARD -88.4% LMNX -43.87% Spread: +31.25 pp (AARD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AARD TTM Op. Margin: 0.0% LMNX TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AARD vs LMNX. Trailing 12-month operating profitability (AARD 0.0% vs LMNX N/A) and valuation multiples (AARD N/M vs LMNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AARD (6) vs LMNX (2)
Institutional Metric AARD LMNX Criterion Row Winner
Market Capitalization Scale $29.1M N/A Larger Scale AARD
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth AARD
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin AARD
Net Profit Margin Profitability 0.0% N/A Higher Margin AARD
Return on Equity (ROE) Capital Efficiency -66.0% N/A Higher ROE AARD
52-Week Range Position Momentum 2% ($1โ€“$17) 5% ($7โ€“$55) Stronger Trend LMNX
Beta / 30D Volatility Risk Regime 4.10ฮฒ ยท 288% Vol 4.92ฮฒ ยท 98% Vol Lower Realized Risk LMNX
Unified Institutional Score Composite Signal 57.5 / 100 (HOLD) 53.5 / 100 (HOLD) Higher Composite AARD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AARD vs LMNX Buy Guide
AARD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AARD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LMNX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LMNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AARD nor LMNX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.